Mission

Mission

Avitide is dedicated to advancing our partners clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.

Avitide partners benefit from:
SPEED.

Delivery of a high yield, high purity molecule-specific affinity resins in 3 months or less. Speed to identify an efficient purification process to reach the clinic faster, and to scale quickly afterwards.

QUALITY.

Beyond capture – bioprocess affinity chromatography resins that can select for product quality attributes or product related isoforms. Affinity ligand selectivity that can dial in specific product profiles for biosimilars, and affinity resins that can bind and elute under gentler conditions than Protein A.

RELIABILITY.

A proactive and robust approach to prevent unpredictable purification challenges from microbial, insect, and mammalian production systems, and from the introduction of upstream process changes/improvements. Avitide enables a monoclonal antibody-like purification process for any biopharmaceutical.

INTELLECTUAL PROPERTY.

Every affinity resin discovery campaign is exclusive to our Partners. Partners receive an exclusive license to key bioprocess technology and intellectual property for the manufacture of biological therapeutics, biosimilars, gene therapies, serum products, and vaccines. A clear strategic advantage and purification platform for companies with diverse biologics and vaccines portfolios.

TECHNOLOGY

TECHNOLOGY

A NEW STANDARD IN SPEED.

Avitide's industry-leading 3-month service and proprietary affinity resin discovery and development technology offers unparalleled speed, performance, and product resolution that will enable bioprocess programs to define a cost-effective affinity purification solution for any class of biopharmaceutical.

A NEW STANDARD IN PRODUCT QUALITY, YIELD, AND PURITY.

On-demand, molecule-specific affinity purification enables high yield and high purity purification processes for gene therapy vectors, vaccines, bispecific antibodies, and therapeutic proteins. Let's move beyond capture: Avitide delivers novel affinity resins that can select for product quality attributes to improve upon drug product purity, safety, and potency.

BIOPROCESS-READY AFFINITY PURIFICATION PERFORMANCE.

Avitide affinity resins are more cost-effective and scalable compared to other affinity ligand and resin manufacturing technologies. The proprietary peptide-based affinity ligands and scaffolds deliver high dynamic binding capacity and cleaning/sanitization stability. To ensure line of sight to commercial resin, affinity ligand manufacturability is assessed very early in the affinity resin discovery and development process (usually within 6 weeks) so that every affinity purification solution delivered is ready to meet the rigors of biopharmaceutical manufacturing.

Avitide-Value-Proposition

Avitide is happy to share case studies on the platform’s capabilities and discuss where we can deliver affinity purification solutions for your clinical and commercial biopharmaceutical programs, life-cycle management projects, and process analytical technology needs

PARTNERING

PARTNERING

COMMITTED TO DEVELOPING LONG-TERM AND STRATEGIC RELATIONSHIPS.

DISCOVERED IN NEW HAMPSHIRE, DELIVERED WORLDWIDE.
1498
LIGANDS DISCOVERED
104
RESINS DEVELOPED
16
RESINS DELIVERED
5
PARTNER CAMPAIGNS
TEAM

TEAM

WE HAVE A PASSIONATE TEAM THAT ENJOYS TACKLING CHALLENGING PROBLEMS.

X

    • Adimab: Head of High Throughput Manufacturing
    • Merck: 10+ Years with Merck Biologics & Vaccines Research and Bioprocess R&D
    • Merck: Senior Engineer at Merck Bioprocess R&D, Automated & High-throughput Bioprocess Technologies
    • Dartmouth College, Thayer Engineering School: Merck-Sponsored Doctoral Fellow

    Kevin Isett, PhD

    Chief
    Executive Officer
    • Dartmouth College, Thayer Engineering School: Senior Research Fellow
    • Glycan Biosciences: Co-Founder and CTO
    • GlycoFi (Acquired by Merck in 2006): Senior Chemist

    Warren Kett, PhD

    Chief
    Scientific Officer
    • Adimab: Co-Founder and CEO
    • Alector: Co-Founder and Chairman of the Board
    • Arsanis: Co-Founder and President
    • GlycoFi (Acquired by Merck in 2006): Co-Founder and CSO
    • Dartmouth College: Professor of Bioengineering and Associate Provost of the Office of Entrepreneurship and Technology Transfer
    • SV Life Sciences: Venture Partner

    Tillman Gerngross, PhD

    Chairman
    of the Board
    • Alector: Director of Finance and Operations
    • Arsanis: Director of Finance and Operations
    • Bedrock Ventures: Founder and Managing Partner
    • Bain Capital Ventures: Analyst
    • McKinsey and Company: Analyst

    Jonathan Sheller

    Director
    Finance & Ops
    • 30+ years in Bioprocess Chromatography Sales and Marketing
    • EMD Millipore: Director of Business Development
    • PerSeptive: Director of Sales and Marketing

    Dan Freymeyer

    Head
    Business Development
CONTACT

CONTACT

LET US KNOW HOW WE CAN HELP.

Call Us 603.965.2100

Visit Us 16 Cavendish Court, Lebanon, NH 03766

AVITIDE SECURES SERIES C

AVITIDE, INC., SECURES SERIES C FINANCING TO EXPAND ON-DEMAND BIOPHARMACEUTICAL AFFINITY PURIFICATION PLATFORM AND ACHIEVE PROFITABILITY NEOMED...

08.06.2015

AVITIDE INC. SECURES SERIES A

AVITIDE INC. SECURES SERIES A FINANCING TO COMMERCIALIZE NOVEL BIOPHARMACEUTICAL AFFINITY PURIFICATION TECHNOLOGY FUNDING FROM BOREALIS, SV...

03.15.2013

Unique biologics pipelines driving biomanufacturing innovation, Deloitte says

June 2, 2015 Zachary Brennan The adoption of new technologies related to single-use bioreactors, disposable plastic containers,...

06.02.2015

Easing Bioprocess Bottlenecks: Solving Bottlenecks May Require More Efficient Scheduling and Digging Deeper into the Workings of Unit Operations

June 1, 2015 Angelo DePalma, Ph.D. Originally conceived as being analogous to what chemists would call a...

06.01.2015

Protein A: expensive but effective say biopharma experts on both sides of the Atlantic

June 20, 2014 Gareth MacDonald Protein A will continue to be a major cost for mAb manufacturers...

06.20.2014